No phaseStatus unknown
Initial dual-drug combination therapy with finerenone, dapagliflozin, or semaglutide in patients with type 2 Diabetes related chronic kidney disease
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
- Enrolment
- 240 planned
- Conditions
- Type 2 diabetes mellitus with diabetic kidney disease
- Interventions
- Combination therapy with dapagliflozin and semaglutide; Combination therapy with finerenone and dapagliflozin; Combination therapy with finerenone and semaglutide
- Ages
- adults, older adults
- Registry
- ChiCTR2600133684
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed 5 October 2026
Primary outcomes
- Change from baseline in estimated glomerular filtration rate (eGFR)
- Change from baseline in urinary albumin-to-creatinine ratio (UACR);
History
Last registry update
Started
Registered